Clinical Research Directory
Browse clinical research sites, groups, and studies.
Rectal NSAIDs With/Without PD Stent for PEP Prevention
Sponsor: Air Force Military Medical University, China
Summary
Pancreatitis is the most common and serious complication following post-endoscopic retrograde cholangiopancreatography (ERCP) and is associated with occasional mortality, extended hospital stays, and increased healthcare expenses. Rectal non-steroidal anti-inflammatory drugs (NSAIDs) and pancreatic duct stent (PDS) placement were demonstrated to be effective strategyies to reduce PEP incidences, particlularly in high-risk patients for post-ERCP pancreatitis (PEP). Rectal NSAIDs were easy-to-use and safe, while PDS placement were technically complex and carried higher risks of adverse events. A previous network meta-analysis suggested rectal NSAIDs in combination with PDS placement did not differ from rectal NSAIDs alone in PEP prevention. To invesigate if rectal NSAIDs alone could obivate the need of PDS placement, a recent trial from Elmunzer et al. conducted a randomized trial to investigate if rectal NSAIDs alone was non-inferior to the combination of NSAIDs with PDS in high-risk patients. The trial found that the PEP incidence rate in combination group was significantly lower than that in NSAIDs alone group. However, post-hoc analysis of the study suggested that the combination strategy conferred significant benefits only in high-risk patients with pancreatic duct (PD) wire passage, but not in those with other risk factors. Therefore, we hypothesized that rectal NSAIDs alone may obivate the need of PDS in high-risk patients without PD wire passages. Here, we conducted a multicenter, randomized and non-inferiority trial to investigate whether rectal NSAIDs alone is non-inferior to NSAIDs plus PDS placement in high-risk patients without PD wire passages.
Official title: Rectal Non-steroid Anti-inflammatory Drugs With or Without Prophylactic Pancreatic Duct Stent for Prevention of Post-ERCP Pancreatitis: a Multicenter, Randomized, Non-inferiority Trial
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
1278
Start Date
2025-07-01
Completion Date
2028-06-01
Last Updated
2025-12-03
Healthy Volunteers
No
Conditions
Interventions
NSAIDs
All patients without contraindications should receive 100mg rectal indomethacin or diclofenac within 30mins before ERCP procedure
NSAIDs plus PDS
All patients without contraindications should receive 100mg rectal indomethacin or diclofenac within 30mins before ERCP procedure. When eligibility is met, PDS placement will be performed by ERCP colonoscopists.
Locations (15)
The first medical center, Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Department of gastroenterology, Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Department of Gastroenterology, Fujian Medical University Xiamen Humanity Hospital
Xiamen, Fujian, China
Harbin Medical University Affiliated Fourth Hospital
Harbin, Heilongjiang, China
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Department of Gastroenterology, Huaihe Hospital of Henan University
Kaifeng, Henan, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
986 Hospital of Xijing Hospital
Xi'an, Shaanxi, China
Xijing of Digestive Diseases
Xi'an, Shaanxi, China
Department of Gastroenterology, The 960th Hospital of the PLA
Jinan, Shandong, China
Shandong Provincial Third Hospital
Jinan, Shandong, China
Department of Endoscopy, Eastern Hepatobiliary Hospital, Second Military Medical University
Shanghai, Shanghai Municipality, China
Affiliated Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
the First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China